---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059355"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:52:17.807608+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q1 revenue $16.6M (+39% YoY); raises FY2024 guidance to $74.5M-$76.5M

## Summary
- Revenue $16.6M, up 39% YoY; 13th consecutive quarter of ≥35% growth.
- OviTex revenue +31% YoY; OviTex PRS +54% YoY.
- Gross margin improved to 68% vs 66% last year; net loss narrowed to $5.7M from $12.0M.
- FY2024 revenue guidance raised to $74.5M-$76.5M (27-31% YoY growth).
- Appointed Howard N. Langstein as VP of Medical Affairs; launched Robotic-Compatible OviTex IHR.

## SEC filing metadata
- accession: 0001104659-24-059355
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924059355/0001104659-24-059355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924059355/tm2411582d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059355
- JSON: https://secwatch.observer/filing/0001104659-24-059355.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059355.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported first quarter ended March 31, 2024 results: revenue $16.6 million, net income $5.7 million. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $16.6 million
  - Net income: $5.7 million
  - Guidance: raised
  - Result: reported results
  source text: Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.3 million in the first quarter of 2024, or 68% of revenue, compared to $7.9 million, or 66% of revenue, in the same period in 2023. The increase in gross margin was primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue due to improvements in inventory management. Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, con
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465924059355/0001104659-24-059355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.